Trial design
type 2 diabetes mellitus
MAY, TYPE 2 DIABETES MELLITUS
This prospective, open-label, non-randomized clinical trial was designed to evaluate the quality of life (QoL) of type 2 diabetes mellitus patients receiving Treviamet® & Treviamet XR® (Sitagliptin with Metformin) in routine care. The Pakistan Medical Association Committee on Ethics approved the study protocol (Ref No. MN/890/LSQ/12) in accordance with the principles outlined in the Declaration of Helsinki. The trial was registered on clinicaltrials.gov (NCT05167513) prior to participant enrollment. The study continued for 12 months, from June 2021 to May 2022, with each participant enrolling for six months, starting from the initiation of therapy until the final assessment.